# Phase 3 Squamous Cell Carcinoma of: 34 recruiting (2026)

ClinicalTrials.gov lists 34 trials in phase 3 for Squamous Cell Carcinoma of Head and Neck that are recruiting or not yet recruiting.

## The full list

Recruiting Phase 3 Squamous Cell Carcinoma of Head and Neck trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/squamous-cell-carcinoma-of-head-and-neck

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 18, 2026 | NCT07827872 | Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827872) |
| August 17, 2026 | NCT07768189 | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma | Corbus Pharmaceuticals Inc. | Phase 3 | Recruiting | Oropharyngeal Carcinoma (OPC) | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768189) |
| August 11, 2026 | NCT07758621 | SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758621) |
| June 25, 2026 | NCT07667296 | APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma | Aveta Biomics, Inc. | Phase 3 | Not yet recruiting | Head and Neck Cancer, Head and Neck (HNSCC), Oropharyngeal, Oral Cavity, Oral Cavity Carcinoma, Oropharynx Squamous... | 826 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667296) |
| May 12, 2026 | NCT07580300 | Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas. | Oslo University Hospital | Phase 3 | Recruiting | HNSCC | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580300) |
| April 3, 2026 | NCT07509099 | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC | Sponsor not shown (see the record) | Phase 3 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509099) |
| March 3, 2026 | NCT07445048 | Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell... | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 3 | Recruiting | Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445048) |
| February 25, 2026 | NCT07432087 | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous... | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432087) |
| January 28, 2026 | NCT07371897 | Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial | Sun Yat-sen University | Phase 3 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma HNSCC | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371897) |
| January 28, 2026 | NCT07371611 | Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma | Sponsor not shown (see the record) | Phase 3 | Recruiting | Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC) | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371611) |
| January 12, 2026 | NCT07333274 | Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck... | Shandong Cancer Hospital and Institute | Phase 3 | Recruiting | Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333274) |
| January 6, 2026 | NCT07320690 | De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 3 | Not yet recruiting | Squamous Cell Carcinoma of the Head and Neck | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07320690) |
| December 11, 2025 | NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head... | Janssen Research & Development, LLC | Phase 3 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276399) |
| December 4, 2025 | NCT07264075 | Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN | Groupe Oncologie Radiotherapie Tete et Cou | Phase 3 | Recruiting | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | 780 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264075) |
| June 18, 2025 | NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC | Universität des Saarlandes | Phase 3 | Recruiting | Recurrent Head and Neck Squamous Cell Carcinoma | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07026474) |
| May 31, 2025 | NCT06998069 | Head and Neck Cancer Study Project in the Geriatric Population | Brown University | Phase 3 | Recruiting | Head and Neck Neoplasms | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06998069) |
| May 28, 2025 | NCT06992427 | High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for... | Alliance for Clinical Trials in Oncology | Phase 3 | Recruiting | Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head... | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06992427) |
| May 6, 2025 | NCT06957938 | Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and... | Fudan University | Phase 3 | Not yet recruiting | Laryngeal Carcinoma, Hypopharyngeal Carcinoma | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957938) |
| November 21, 2024 | NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell... | Rakuten Medical, Inc. | Phase 3 | Recruiting | Recurrent Head and Neck Squamous Cell Carcinoma | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699212) |
| October 18, 2024 | NCT06647563 | Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 3 | Not yet recruiting | Squamous Cell Carcinoma of Head and Neck | 355 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06647563) |
| September 19, 2024 | NCT06601335 | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Akeso | Phase 3 | Recruiting | Head and Neck Squamous Cell Carcinoma | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06601335) |
| September 19, 2024 | NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck... | National Cancer Institute (NCI) | Phase 3 | Recruiting | Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic... | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06589804) |
| July 9, 2024 | NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | Sun Yat-sen University | Phase 3 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492460) |
| February 14, 2024 | NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | Sponsor not shown (see the record) | Phase 3 | Recruiting | Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06258811) |
| February 13, 2024 | NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell... | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Head and Neck | 864 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06256588) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 3 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Sun Yat-sen University | 2 |
| Aveta Biomics, Inc. | 1 |
| Fudan University | 1 |
| Johnson & Johnson Enterprise Innovation Inc. | 1 |
| Radboud University Medical Center | 1 |
| Brown University | 1 |
| Beijing Tongren Hospital | 1 |
| National Cancer Institute (NCI) | 1 |
| UNICANCER | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Groupe Oncologie Radiotherapie Tete et Cou | 1 |
| Lepu Biopharma Co., Ltd. | 1 |
| Oslo University Hospital | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| Shandong Cancer Hospital and Institute | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Corbus Pharmaceuticals Inc. | 1 |
| Lund University Hospital | 1 |
| [AVEO Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/aveo-pharmaceuticals-inc) | 1 |
| Rakuten Medical, Inc. | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| Universität des Saarlandes | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 17 |
| United States | 9 |
| France | 7 |
| Germany | 6 |
| Taiwan | 6 |
| Belgium | 5 |
| Hungary | 5 |
| Romania | 5 |
| South Korea | 5 |
| Spain | 5 |
| United Kingdom | 5 |
| Canada | 4 |
| Czechia | 4 |
| Japan | 4 |
| Portugal | 4 |
| Italy | 4 |
| Austria | 3 |
| Brazil | 3 |
| India | 3 |
| Sweden | 3 |
| Netherlands | 3 |
| Australia | 3 |
| Poland | 3 |
| Bulgaria | 2 |
| Greece | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
- [Cafeterias in the United States](https://specstream.ai/data/businesses/cafeterias/united-states)
- [Career counseling services in the United States](https://specstream.ai/data/businesses/career-counseling-services/united-states)
- [Cement suppliers in the United States](https://specstream.ai/data/businesses/cement-suppliers/united-states)
- [Child care centers in the United States](https://specstream.ai/data/businesses/child-care-centers/united-states)
